Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | PRESTO: the benefits of intensifying treatment in prostate cancer

Ronald Chen • 1 Jun 2024
ASCO 2024
Genitourinary Cancer Prostate Cancer Apalutamide
PRESTO

Ronald Chen, MD, MPH, University of Kansas Medical Center, Kansas City, KS, comments on the findings from the Phase III PRESTO trial (NCT03009981), which assessed intensified androgen receptor blockade in patients with biochemically relapsed prostate cancer post-radical prostatectomy. Addition of apalutamide to androgen deprivation therapy (ADT) improved PSA control without compromising quality of life, showing that intensifying treatment can benefit patients, with can also result in fewer subsequent treatments. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Abbvie; Accuray; Accuray; Astellas Pharma; Bayer; Blue Earth Diagnostics; Genentech; Janssen; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding – Accuray
Travel, Accommodations, Expenses – Reflexion Medical; Telix Pharmaceuticals

More from Ronald Chen

Aggressive care at the end-of-life for younger cancer patients: ASCO's Choosing Wisely campaign
4:25
Aggressive care at the end-of-life for younger cancer patients: ASCO's Choosing Wisely campaign
Ronald Chen • 3 Jun 2016

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals